Physician profile

Jonathan J Berry

Cardiovascular Disease · Greensboro, NC

NPI 1235237926

$8,526.42

in general payments reported to CMS, 2019-2025

41 companies · $614 in 2025

The $614 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,837.43
Education$17.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $993.49 2019-2025 Repatha, Repatha
Medtronic, INC. $863.99 2021-2025 Onyx Frontier, Hawkone, In.Pact Admiral
Novartis Pharmaceuticals Corporation $699.91 2019-2025
Shockwave Medical, INC $559.12 2020-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Abbott Laboratories $428.85 2019-2024 Pressurewire, Diamondback Peripheral, Cardiomems
Cardiovascular Systems INC. $422.93 2019-2022
Abiomed $385.06 2022-2025 Impella
Janssen Pharmaceuticals, INC $377.35 2019-2024 Xarelto
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $316.52 2019-2024 Lifevest
Penumbra, INC. $300.47 2019-2022
Irhythm Technologies, INC. $293.36 2019-2024 Zio Xt Patch, Zio Monitor
Astrazeneca Pharmaceuticals LP $288.90 2019-2025 Wainua, Farxiga
Boehringer Ingelheim Pharmaceuticals, INC. $282.24 2019-2024 Jardiance
Teleflex LLC $227.55 2019-2025 Twin-Pass
Pfizer INC. $226.71 2019-2024
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $218.99 2019-2024 Watchman Flx, Eluvia
Sanofi-Aventis U.S. LLC $207.17 2019-2023
Heartflow, INC. $199.53 2023-2024 Ffrct
Angiodynamics, INC. $144.25 2020
E.R. Squibb & Sons, L.L.C. $127.64 2019-2025 Camzyos
Scpharmaceuticals INC. $122.48 2023-2025
Terumo Medical Corporation $110.70 2023 Heartrail, Metacross Otw, Glidewire
Acist Medical Systems, INC. $101.07 2024
Alnylam Pharmaceuticals INC. $73.89 2023-2024 Onpattro
Kiniksa Pharmaceuticals International, Plc $64.68 2024 Arcalyst
Atricure, INC. $62.42 2023
Merck Sharp & Dohme LLC $56.79 2021-2022
Cvrx, INC. $47.67 2021-2023 Barostim Neo System
Lundbeck LLC $47.20 2019
Medtronic Vascular, INC. $37.51 2019-2020
Daiichi Sankyo INC. $37.17 2023 Injectafer
Regeneron Healthcare Solutions, INC. $30.73 2019
Chiesi USA, INC. $24.45 2019
Lexicon Pharmaceuticals, INC. $24.30 2024
Portola Pharmaceuticals, LLC $23.35 2019
Philips North America LLC $20.58 2023
Kestra Medical Technology Services, INC. $18.25 2024 Assure Wcd
Gilead Sciences, INC. $16.06 2019
Esperion Therapeutics, INC. $15.76 2024 Nexletol
Bayer Healthcare Pharmaceuticals INC. $15.63 2023
W. L. Gore & Associates, INC. $11.70 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jonathan J Berry

$8,526.42

in general payments reported 2019-2025

Years
2019-2025
Top company
Amgen INC.
Context
The $614 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/11200/jonathan-j-berry

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.